INTRODUCTION 1
The isolation of broadly neutralizing antibodies against influenza A viruses has 2 reinforced the notion that development of a universal influenza virus vaccine is, in 3 principle, possible (8, 9, 13, 20, 36, 39, 45) . Broadly neutralizing antibodies are 4 protective against multiple viral subtypes and generally recognize epitopes in the 5 highly conserved membrane-proximal region of hemagglutinin (HA). This interaction 6 inhibits infection by preventing fusion of the viral and cellular membranes (9, 12, 13, 7 36 ). In contrast, most antibodies elicited in response to the current vaccines bind to 8 immunodominant epitopes located in the membrane-distal head of HA and prevent 9 receptor binding and entry of the virus (2, (15) (16) (17) . The HA head is highly variable, 10 explaining the lack of protection against viruses that do not closely correspond to the 11 vaccine strain. The specific epitopes recognized by broadly neutralizing antibodies, 12 such as CR6261 (12) , F10 (36) , CR8020 (13) and FI6v3 (9) , have been identified and 13 their structures in complex with their cognate antibodies revealed by X-ray 14 crystallography (Fig. 1A) . The challenge now resides in developing antigens that 15 present these epitopes to the immune system in a way that induces a potent and 16 protective antibody response. 17 We and others have shown that icosahedral, virus-like particles (VLP) represent 18 highly effective platforms for the development of novel vaccines (4, 19, 21, 24, 30, 31, 19 38) . Icosahedral virus particles are known to be strongly immunogenic based on the 20 repetitive array of their component proteins, particulate nature, and ability to 21 appropriately stimulate the innate immune response. By using genetic engineering and 22 structure-based design, we have developed the T=3 icosahedral insect virus Flock 23 in the supernatant were pelleted through a 30% (wt/wt) sucrose cushion in 50 mM 1
Hepes pH 7 at 184,000 x g for 2.5 hr at 11°C and resuspended in 50 mM Hepes pH 7 2 containing protease inhibitors (Roche). Resuspended pellets were treated with RNaseA 3 for 30 min. at 37°C, and then centrifuged at 16,100 x g for 10 min. at 4°C. The 4 supernatant was loaded onto 10-40% (wt/wt) sucrose gradients in 50 mM Hepes pH 7 5 and centrifuged at 197,568 x g for 1.5 hr at 11 °C. VLPs were harvested from the 6 gradients by needle puncture and stored at -20 °C. 7 
8
Cloning, expression and purification of hemagglutinins. Based on H3 numbering, 9 cDNAs corresponding to residues 11-329 (HA1) and 1-176 (HA2) of the ectodomain of 10 the HA were fused to an N-terminal gp67 signal peptide and to a C-terminal 11 biotinylation site (amino acid sequence: GGGLNDIFEAQKIEWHE), trimerization 12 domain, and His-tag by overlap PCR, essentially as previously described (12) . The 13 trimerization domain and His-tag were separated from the HA ectodomain by a 14 thrombin cleavage site. The resulting PCR products were digested with SfiI and 15 inserted into a custom baculovirus transfer vector (pDCE066 or 16 pDCE198). Recombinant bacmid was generated using the Bac-to-Bac system 17 (Invitrogen) and virus was rescued by transfecting purified bacmid DNA into Sf9 cells 18 using Cellfectin II (Invitrogen). HA protein was produced by infecting suspension 19 cultures of Hi5 cells (Invitrogen) with recombinant baculovirus at an MOI of 5-10 and 20 incubating at 28°C shaking at 110 RPM. After 72 hours, the cultures were clarified by 21 two rounds of centrifugation at 2000 x g and 10,000 x g at 4 °C. The supernatant, 22 containing secreted, soluble HA was concentrated and buffer exchanged into 1x PBS, pH 23 on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from 7.4. After metal affinity chromatography using Ni-NTA resin, HAs were digested with 1 trypsin (New England Biolabs, 5mU trypsin per mg HA, 16 hours at 17°C) to produce 2 uniformly cleaved (HA1/HA2), and to remove the trimerization domain and His-3 tag. After quenching the digests with 2mM PMSF, the digested material was further 4 purified by size exclusion chromatography (10mM Tris, pH 8.0, 150mM NaCl). 5
6
Electron cryo-microscopy, data collection and image reconstruction of VLPs. 7
Frozen hydrated samples of purified VLPs at 5 mg ml -1 were prepared on C-flat CF-22-8 4C grids (Protochips). Briefly, a 5 l sample was applied to a freshly plasma cleaned 9 grid, the grid was blotted for 5 seconds using an FEI Vitrobot instrument, and quickly 10 plunged into a bath of liquid ethane at -180C. Grids were handled and stored under 11 liquid nitrogen. Cryo-EM data were collected at the National Resource for Automated 12 Molecular Microscopy using the LEGINON suite operating an FEI Tecnai F20 electron 13 microscope (37). Images were collected at a nominal magnification of 80,000x, a 14 defocus range of -1.2 to -2.5 m, and a high tension of 120 kV onto a Gatan 4k-by-4k 15 charge-coupled device (CCD). The pixel size of the CCD was calculated using the 16 diffraction pattern from a 2D catalase crystal with known cell parameters. Contrast 17 transfer function estimation was done with ctffind3 (27) and correction was done with 18 ACE2 through the Appion package (22, 37) . Particle picking was done using DoG Picker 19 (41) . A 25Å resolution electron density map calculated from the deposited structure of 20 FHV (PDB entry: 2Q26) served as the starting model for image reconstruction using the 21 EMAN package (23) . The resolution of the image reconstructions, at an FSC of 0. were fitted into the moderate resolution particle density using the program Coot (14) . 3
The models were converted to polyserine residues for more flexible fitting. Coordinates 4 for the majority of the FHV coat protein fit the density without modification. The insert 5 at 264 was disordered after the first few residues and was placed in random 6 orientations in the final model for visualization purposes only. The insert at 206 was 7 fitted using a combination of real-space refinement and manual adjustments. Biomedicals, LLC). Two weeks after priming, mice were boosted with the same amount 22 of particles infused with incomplete Freund's adjuvant (MP Biomedicals, LLC). Serum 23 was prepared from whole blood collected retro-orbitally ten days post prime and boost 1 immunizations. Mice were challenged via the intranasal route two weeks after the 2 boost with five 50% mouse lethal doses (mLD50) of mouse-adapted PR8 (H1) in a total 3 volume of 20 µl. Body weight was monitored daily and mice that lost more than 25% of 4 their original body weight were sacrificed and marked as dead. In experiment 4 ( Figure  5 Serum was prepared from whole blood collected from the submandibular vein prior to 10 each injection as well as two weeks after the final immunization (week 8). 11
12
ELISA. Sera collected from mice in immunization experiments 1, 2 and 4 were tested 13 using the ELISA protocol described by Manayani et al. (24) . Briefly, 0.5-1 g antigen 14 (purified wt FHV VLPs, purified MBP-B2 fusion protein or purified, trypsin-cleaved 15 trimeric HA) in 0.1M NaHCO3 was used to coat wells of a 96-well Immulon microtiter 16 plate (Thermo Scientific) for 1 hr at room temperature followed by blocking overnight 17 at 4°C in 3% non-fat milk in TBS (pH7). Mouse sera were diluted 1:100, 1:1000 or 18 1:10,000 in 1% non-fat milk in TBS with 0.05% Tween 20. Goat anti-mouse antibody 19 coupled to horseradish peroxidase was used as a secondary antibody and antibody 20 binding was quantified with TMB substrate. Color development was stopped after 21 incubation for 10 min at 37°C by addition of HCl and signal was quantified by 22 measuring absorbance at 450 nm. 23 Sera collected from mice in experiment 3 were tested using the following ELISA 1 protocol: purified hemagglutinin (2.5 µg/ml) in PBS was used to coat wells of a 96-well 2 EIA/RIA plate (no. 3590; Corning, Inc.) using 50 µl per well. Plates were incubated at 3 4°C overnight, washed three times with 0.1% Tween-20/1X PBS and blocked with 200 4 µl of 5% non-fat milk/1X PBS for 30 minutes at room temperature (RT). Serial dilutions 5 of sera were added and plates incubated for two hours at room temperature. Plates 6 were washed three times and an anti-mouse IgG-HRP secondary antibody (1:5000; 7 NA931V, GE Healthcare) was added and plates incubated for 1 hour at 37°C. After the 8 plates were washed three times, 200 µL of o-phenylenediamine dihydrochloride 9 (Sigma) substrate was added and plates read at 405 nm. 10 11 SDS-PAGE and immunoblot analysis. SDS-PAGE and immunoblot were carried 12 out as described previously (11) . Briefly, purified, trypsin-cleaved SC1918HA (1g) and 13 wt FHV VLPs (1g) were electrophoresed through neighboring lanes of a 12% Laemmli 14 gel and transferred to nitrocellulose. Transfer was overnight at 20 mA. Membranes 15 were blocked in PBS containing 5% non-fat dry milk and then incubated with a 100-fold 16 dilution of indicated mouse sera. Secondary antibody was HRP-conjugated goat anti-17 mouse (cat. no. 115-035071; Jackson Immunoresearch) used at a 1:4000 dilution. 18 Immune complexes were visualized by enhanced chemiluminescence (SuperSignal; 19 ThermoScientific) and exposure to X-ray film. 20
RESULTS 1
Design and synthesis of VLPs displaying the influenza A-helix. The A-helix forms 2 the major part of a functionally conserved epitope in the membrane proximal stalk of 3 influenza virus hemagglutinin. To elicit a potent antibody response against this helix, 4
we chose to present it to the immune system in a polyvalent manner on the surface of 5 FHV VLPs, which are known to be highly immunogenic (24) . Two small loops on the 6 FHV particle surface, residues 206-208 and 264-268 (Fig. 1B) , were chosen as 7 exogenous protein insertion sites based on several key properties: high solvent 8 exposure, trimeric arrangement (particularly position 206) after particle assembly, 9 flexible polypeptide termini in close proximity after the loops are removed, and proven 10 ability to accommodate insertions without affecting particle assembly. Simply inserting 11 the A-helix coding sequence (KSTQNAIDGITNKVNSVIEK) into these surface loops, 12 however, was unlikely to preserve its helical conformation. We, therefore, selected 13 protein B2, a small helix-turn-helix non-structural protein also encoded by FHV (6), as a 14 scaffold for maintaining the secondary structure of the A-helix peptide ( Fig. 2A) (Fig. 2B) . The A-helix 19 was positioned with respect to the B2 helical turns in order to maximize solvent 20 exposure of the CR6261 contact residues by putting them on the outward facing 21 surfaces of the insert (Fig. 2C) . Coordinates for the designed B2/A-helix chimera were 22 then inserted at FHV positions 206 and 264 ( Fig. 2D) and models of the full icosahedral 23 particles were generated. Evaluation of the particle models showed no potential 1
properties that would interfere with assembly of the VLP or display of the inserted 2 antigens. The inserts were expected to be vertically oriented at position 206 due to 3 their close proximity to one another (~8Å) and the native -strands that start the loop. 4
Although no changes to the virus or insert sequences were made to promote 5 interactions between them, we were aspiring to produce a trimeric stem-like structure 6
by placing them at the quasi 3-fold axes of the particle. The inserts at position 264 are 7 10Å further from the quasi 3-fold axis, which separates them ~14Å from one another, was composed of three copies of the insert and that they had established fortuitous 2 inter-helical contacts to stabilize their vertical protrusion from the particle surface. The 3 spikes made contact at their distal tips across the particle 2-fold axes, which also may 4 have stabilized their rigid structures but, consequently, blocked access to one of the A-5 helix sites in each spike. 6
The initial model of VLPs with the insert at position 206 (hereafter referred to as 7 VLP-206) ( Fig. 2D) was fitted into the image reconstruction using a combination of 8 automated and manual procedures in order to obtain its actual structure and provide a 9 basis for interpreting the resulting immunogenic properties of the inserted B2/A-helix 10 antigen. The resulting fit of the 206 particle density ( Fig. 3A and B) indicated that the 11 inserts twist about each other slightly at their midpoints, and the exposed tips point 12 outward resulting in a slight bend of the A-helix. Importantly, the fit to density 13 indicated that the B2/A-helix insert had retained its helical structure and exposed the 14 A-helix on two of the three faces of the spike in the VLP-206 particles. 15
In contrast, the reconstructed image of VLPs with the inserts at position 264 16 (hereafter referred to as VLP-264) ( Fig. 2H) was closely similar to an unmodified FHV 17 capsid (e.g. Fig. 1B ), demonstrating that the inserts at the 264 site did not form any 18 icosahedrally ordered structures. Instead, the lack of density indicated that they adopt 19 diverse orientations across the surface of the particles. Fitting of coordinates 20
representing the B2/A-helix insert was not possible at the 264 insertion site due to the 21 disordered density; thus, the three inserts were each aligned differently in the VLP-264 22 model to visualize a particle with variably oriented inserts (Fig. 3C) . It suggested the 23 inserts formed an irregular, unstructured sheath over the VLP-264 surface, potentially 1 giving the A-helix more varied and possibly greater exposure compared to the 206 2 particle. However, it was not possible to determine if the epitope was helical or 3 accessible on the 264 particle surface. Taken together, the B2/A-helix scaffold designs 4 were successful in: 1) creating correctly folded coat protein chimeras that 2) assembled 5 into icosahedral particles, and 3) prominently displayed the B2/A-helix inserts at both 6 the 206 and 264 sites, with the former adopting a trimeric oligomerization of the 7 helices. 8
Monoclonal antibodies CR6261 (Fab fragment) and F10 (complete IgG) were 9 used as tools to further probe the conformation of the inserts, but neither bound to the 10 VLPs (data not shown). Given that these antibodies also failed to bind to a synthetic 11 peptide representing the A-helix (data not shown), CR6261 and F10 may require 12 additional HA1 and HA2 residues from their epitopes to form stable interactions with 13 an antigen. Thus, the VLPs were expected to elicit anti A-helix antibodies distinct from 14 those of CR6261 or F10 since the particles did not display the complete epitope 15 recognized by these antibodies. 16
Immune response to chimeric VLPs. Balb/c mice (4 per group) were immunized 18 three times in intervals of three weeks with 10 g of purified VLP-206, VLP-264 or PBS 19 as a control. No adjuvants were used in this study based on previous observations that 20 the particles are strongly immunogenic (24) .
Blood was collected prior to each 21 injection as well as two weeks after the final boost and serum was tested by ELISA for following the same injection schedule. In this group, two of six mice generated 11 antibodies to trimeric HA (Fig. 5) . As with the VLP-264 results, the anti-HA titer was 12 considerably lower than those against the FHV and B2 proteins. Thus, both VLPs were 13 capable of eliciting an anti-HA IgG response in mice. Although non-uniform and 14 relatively weak, it indicated that the A-helix is presented on the surface of both particles 15 in a manner related to its structure and exposure in the HA stalk. 16 Nonetheless, to exclude the possibility that positive HA ELISA data reflected an 17 antibody response to a linear, non-helical A-peptide as a result of partial denaturation 18 of HA antigen during the assay, week 8 sera from all animals were tested for reactivity 19 against denatured HA and FHV coat protein by immunoblot analysis (Fig. 6) . The sera 20 reacted to varying degrees with denatured FHV coat protein indicating the presence of 21 linear epitopes in the three-dimensional structure of the protein. In contrast, only one 22 serum, that of animal #9, reacted with denatured HA2 (Fig. 6, panel A) . Taken Freund's adjuvant and boosted once two weeks after the first immunization. Ten days 10 after primary and secondary immunizations blood was collected and serum tested by 11 ELISA against trimeric HA representing group 1 subtypes H1 (Cal/09), H2 (Sg/57) and 12 H5 (VN04) and group 2 subtype H3 (HK/68). In this study all five mice injected with 13 VLP-264 showed measurable but still relatively weak responses against all tested group 14 1 subtypes, particularly after the boost (Fig. 7) . There was no response against the H3 15 subtype in the inoculated mice or against any subtype by the control mice. with the mouse-adapted strain A/Puerto Rico/8/34 (H1N1) (Fig. 8) . 7 Inability of the sera to neutralize influenza virus both in vitro and in vivo 8 prompted us to compare the amino-acid sequence of the A-helix displayed on the VLPs 9 with those of the HAs used in the ELISA, micro-neutralization and mouse challenge 10 assays. Except for the HA with the matching A-helix employed as antigen in our initial 11 ELISA experiments (Fig. 4 and 5) , A-helices in all other HAs contained at least one 12 amino acid change relative to SC1918 HA (Fig. 1C) adjuvant. Blood was collected prior to each injection and two weeks after the final 7 boost in week 8. Only week 8 serum samples were tested by ELISA using trimeric PR8 8 HA as an antigen. As with the VLPs presenting the SC1918/H1 A-helix, the VLPs 9 presenting the PR8 A-helix elicited antibodies that bound trimeric HA (Fig. 9A) . 10 Interestingly, the group of animals immunized with both types of particles showed a 11 greater number of anti A-helix responders and had a higher average titer. 12
Mouse sera that reacted with PR8 HA (H1) by ELISA were also tested for 13 reactivity against H5 HA (group 1) and H3 HA (group 2). Except for one animal (#32), 14 all sera recognized H5, but not H3 HA due to its glycosylation (Fig. 9B) , consistent with 15 the specificity expected for antibodies raised against the conserved exposed face of the 16 A-helix. In immunoblot analysis, two of the nine positive sera, reacted weakly with 17 denatured HA2 (animals 16 and 19), while one serum (animal 31) showed a stronger 18 signal (data not shown). These results were consistent with previous observations that 19 showed the VLPs displayed the A-helix in a near native conformation and that positive 20 ELISA data could not generally be ascribed to the presence of antibodies that 21 recognized denatured hemagglutinin. However, despite these encouraging binding 22 characteristics, the sera were unable to neutralize PR8 virus in a microneutralization 23 assay (data not shown). Challenge of immunized animals with live virus was therefore 1 not pursued. and may one day be used in combination. 13 We have employed a structure-based approach to design an antigen that mimics 14 the major determinant of a highly conserved epitope in the membrane-proximal stem of 15 influenza virus hemagglutinin. Our work had two main objectives: first, to determine 16 whether linear, helical epitopes can be presented as a stable structure on the surface of 17 an icosahedral virus-like particle and second, to test the hypothesis that the A-helix of 18 influenza virus hemagglutinin is sufficiently immunogenic to induce broadly 19 neutralizing antibodies. to B cells (25) . Finally, the VLP platform permits multivalent display of heterologous 7
proteins and peptides, a feature known to improve immunogenicity by promoting 8 crosslinking of B cell receptors. 9
To retain the secondary structure of the A-helix, we employed the small helix-10 turn-helix protein B2 as a scaffold. The value of scaffolding proteins for presentation of 11 epitopes in their native conformation has been demonstrated previously (7, 26, 28) . B2 12 normally forms antiparallel homodimers that bind tightly to dsRNA and inhibit RNA 13 interference in FHV-infected cells (6) . The structure of the monomer was ideally suited 14 for insertion into the FHV loops because slight truncations brought its N and C termini 15 into close enough proximity to match the distance between FHV loop residues to which 16 connections had to be made. Also, there are no specific interactions between the 17 hydrophobic residues lining the inner surfaces of the long and short helices in 18 monomeric B2, suggesting that helical segments could be exchanged without disrupting 19 the hairpin motif. CryoEM analysis and image reconstruction of the chimeric VLPs 20 revealed the VLP-206 inserts retained the helix-turn-helix motif as highly exposed 21 vertical columns on the particle surface. In contrast, the VLP-264 inserts had random 22
orientations, yet were also able to elicit antibodies that recognized trimeric HA and B2 23 proteins, providing strong evidence that the inserts maintained the helix-turn-helix 1 motif. 2 We vaccinated mice with the two types of VLP using various immunization 3 schedules and amounts of antigen in the presence or absence of two kinds of adjuvant. 4 We collected blood at different times after primary and secondary injections. The IgG 5 response to FHV coat protein and scaffolding protein B2 was consistently rapid and 6 robust, whereas the response to the A-helix was slow, much weaker and non-uniform. 7
While both types of particles elicited anti A-helix antibodies, VLP-264 produced higher 8 responses perhaps due to the flexible nature of the insert at that site or because some 9
A-helices in VLP-206 are partially blocked due to the interaction of the inserts across 10 the two-fold axes of symmetry. Enhanced immunogenicity of flexible epitopes relative 11 to rigidly displayed epitopes has been observed previously for protein scaffolds 12 displaying the MPER epitope of HIV-1 gp41 (28). 13 We employed trimeric, fully cleaved HA (i.e HA1/HA2, not HA0) in ELISA assays 14 to probe for the presence of anti A-helix antibodies. This was based on the assumption 15 that such antibodies would also bind to HA in its native environment, such as influenza 16 virus particles or HA on the surface of virus-infected cells. However, given the weak 17 response, we were concerned that this strategy under-estimated the true level of anti A-18 helix antibodies if a significant portion had been elicited to non-native A-helix 19
conformations. This possibility could be largely excluded, however, by demonstrating 20 that, with few exceptions, sera were negative for binding to denatured HA2 by 21 immunoblot analysis. Instead, anti A-helix antibodies elicited by VLPs appeared to be 22 structurally specific for the A-helices in natively folded HA molecules. 23 The notion that anti A-helix antibodies elicited in response to vaccination with 1 VLPs were structurally specific for the same A-helix conformation as monoclonal 2 antibodies CR6261 and F10 was further supported by the observation that they reacted 3 with HA representing different subtypes in phylogenetic group 1, such as H1, H2 and 4 H5, but not group 2, such as H3. However, in contrast to CR6261 and F10, the anti A-5 helix antibodies did not neutralize influenza virus in vitro nor did they protect 6 immunized mice from challenge with live virus. The reason for this discrepancy is not 7 yet known and a detailed understanding will have to await isolation of monoclonal anti 8
A-helix antibodies and characterization of their interaction with HA. Based on current 9 data, a simple explanation would be that serum levels of the required antibodies were 10 insufficient. Alternatively, low affinity/avidity of the antibodies or potential steric 11 of this is that antibodies may use an angle of approach to contact the A-helix on VLPs 22 that makes it impossible for them to access the A-helix in the context of HA that is 23 anchored to a viral or cellular membrane (Fig. 10) . If so, this problem could be 1 resolved by transferring the A-helix in the VLP to the opposite side of the helix-turn-2 helix scaffold in order to reverse its orientation. That said, given the weak and 3 inconsistent antibody response to the A-helix in immunized mice, it will also be 4 important to investigate whether presentation of helical epitopes in a vertical helix-5 turn-helix motif impedes interaction of B cell receptors with the helix of interest 6 thereby resulting in poor overall responses. 7
Finally, we cannot exclude the possibility that the A-helix alone is not sufficient 8
as an antigen to induce broadly neutralizing antibodies. Incorporating additional 9 regions of the CR6261 epitope into the VLP display platform will test this possibility. Freund's adjuvant and boosted two weeks later were challenged with 5 MLD50 of 11 mouse-adapted H1 virus strain PR8 two weeks after secondary immunization. Body 12 weight was monitored daily and mice that lost more than 25% of original body weight 13 were sacrificed and marked as dead. Immune response of these mice to HA is shown in 14 figure 7. 15 
